InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has entered into a securities purchase agreement with an institutional investor to raise approximately US$12.0 million through the issuance of an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant in a private placement priced at-the-market under Nasdaq rules. The closing of the private placement is expected to occur on or about July 2, 2021, subject to satisfaction of customary closing conditions.
RBC Capital Maintains Outperform on Trade Desk, Raises Price Target to $80
RBC Capital analyst Matthew Hedberg maintains Trade Desk (NASDAQ:TTD) with a Outperform and raises the price target from $75 to $80.
